Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 14(1): 14591, 2024 06 25.
Article in English | MEDLINE | ID: mdl-38918503

ABSTRACT

Hypodense volumes (HDV) in mediastinal masses can be visualized in a computed tomography scan in Hodgkin lymphoma. We analyzed staging CT scans of 1178 patients with mediastinal involvement from the EuroNet-PHL-C1 trial and explored correlations of HDV with patient characteristics, mediastinal tumor volume and progression-free survival. HDV occurred in 350 of 1178 patients (29.7%), typically in larger mediastinal volumes. There were different patterns in appearance with single lesions found in 243 patients (69.4%), multiple lesions in 107 patients (30.6%). Well delineated lesions were found in 248 cases (70.1%), diffuse lesions were seen in 102 cases (29.1%). Clinically, B symptoms occurred more often in patients with HDV (47.7% compared to 35.0% without HDV (p = 0.039)) and patients with HDV tended to be in higher risk groups. Inadequate overall early-18F-FDG-PET-response was strongly correlated with the occurrence of hypodense lesions (p < 0.001). Patients with total HDV > 40 ml (n = 80) had a 5 year PFS of 79.6% compared to 89.7% (p = 0.01) in patients with HDV < 40 ml or no HDV. This difference in PFS is not caused by treatment group alone. HDV is a common phenomenon in HL with mediastinal involvement.


Subject(s)
Hodgkin Disease , Mediastinal Neoplasms , Humans , Male , Female , Hodgkin Disease/pathology , Hodgkin Disease/diagnostic imaging , Adult , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/diagnostic imaging , Middle Aged , Tomography, X-Ray Computed , Young Adult , Aged , Adolescent , Mediastinum/pathology , Mediastinum/diagnostic imaging , Fluorodeoxyglucose F18 , Positron-Emission Tomography , Progression-Free Survival
2.
Pediatr Blood Cancer ; 70(8): e30421, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37243889

ABSTRACT

BACKGROUND: Rebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemotherapy (CTX) or radiotherapy, with an incidence between 44% and 67.7% in pediatric lymphoma. Misinterpretation of RTH and thymic lymphoma relapse (LR) may lead to unnecessary diagnostic procedures including invasive biopsies or treatment intensification. The aim of this study was to identify parameters that differentiate between RTH and thymic LR in the anterior mediastinum. METHODS: After completion of CTX, we analyzed computed tomographies (CTs) and magnetic resonance images (MRIs) of 291 patients with classical Hodgkin lymphoma (CHL) and adequate imaging available from the European Network for Pediatric Hodgkin lymphoma C1 trial. In all patients with biopsy-proven LR, an additional fluorodeoxyglucose (FDG)-positron emission tomography (PET)-CT was assessed. Structure and morphologic configuration in addition to calcifications and presence of multiple masses in the thymic region and signs of extrathymic LR were evaluated. RESULTS: After CTX, a significant volume increase of new or growing masses in the thymic space occurred in 133 of 291 patients. Without biopsy, only 98 patients could be identified as RTH or LR. No single finding related to thymic regrowth allowed differentiation between RTH and LR. However, the vast majority of cases with thymic LR presented with additional increasing tumor masses (33/34). All RTH patients (64/64) presented with isolated thymic growth. CONCLUSION: Isolated thymic LR is very uncommon. CHL relapse should be suspected when increasing tumor masses are present in distant sites outside of the thymic area. Conversely, if regrowth of lymphoma in other sites can be excluded, isolated thymic mass after CTX likely represents RTH.


Subject(s)
Hodgkin Disease , Lymphoma , Thymus Hyperplasia , Thymus Neoplasms , Humans , Child , Hodgkin Disease/diagnostic imaging , Hodgkin Disease/drug therapy , Hodgkin Disease/complications , Thymus Hyperplasia/diagnostic imaging , Thymus Hyperplasia/etiology , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Recurrence, Local/drug therapy , Lymphoma/drug therapy , Tomography, X-Ray Computed , Positron-Emission Tomography/methods , Thymus Neoplasms/diagnostic imaging , Thymus Neoplasms/drug therapy , Thymus Neoplasms/complications , Fluorodeoxyglucose F18/therapeutic use , Radiopharmaceuticals
SELECTION OF CITATIONS
SEARCH DETAIL
...